文献速递口腔修复与种植牙周病

肝移植免疫抑制患者种植治疗的前瞻性对照研究

Implant treatment in pharmacologically immunosuppressed liver transplant patients: A prospective-controlled study.
PubMed 文献 · Clin Oral Implants Res · 2017-07-21

这项前瞻性对照研究评估了肝移植患者(LTP)种植治疗的长期结局,16例药物免疫抑制LTP与16例匹配对照分别植入52枚和54枚种植体,平均随访超过8年。结果显示两组早期术后并发症相似,LTP组种植体存活率100%、对照组98.15%,种植体周围黏膜炎和种植体周围炎发生率两组间未见明显差异。结论认为药物免疫抑制并非种植失败或种植体周围疾病的风险因素,肝移植不是种植治疗的禁忌证,但需密切随访监测。

要点

  • 肝移植患者种植体存活率100%,对照组98.15%,免疫抑制未增加种植失败风险。
  • 两组早期术后并发症相似,种植体周围黏膜炎和种植体周围炎发生率无显著差异。
  • 肝移植不是种植禁忌证,但此类患者随访期需密切监测。

核心结论

  • 药物免疫抑制的肝移植患者不是种植失败或种植体周围疾病的风险因素。
  • 肝移植不是牙种植治疗的禁忌证,但随访期需仔细监测。

研究设计与样本

  • 前瞻性对照研究,纳入16例药物免疫抑制肝移植患者和16例匹配对照。
  • 两组分别植入52枚和54枚种植体,种植时间为1999年至2008年。
  • 评估术后愈合后平均随访超过8年,记录影像学、临床和牙周参数。

主要发现

  • 两组早期术后并发症相似。
  • 种植体存活率LTP组为100%,对照组为98.15%。
  • 种植体周围黏膜炎在LTP组累及35.42%的种植体和64.29%的患者,对照组为43.40%的种植体和56.25%的患者。
  • 种植体周围炎在LTP组累及4.17%的种植体和7.10%的患者,对照组为9.43%的种植体和18.80%的患者。

临床怎么用

  • 肝移植患者可考虑种植治疗,但需在随访中密切监测种植体周围状况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The main objective of this prospective study was to evaluate the long-term outcome of implant therapy in liver transplant patients (LTP). The secondary goal was to assess several implant- and patient-dependent variables, such as peri-implantitis (PI), peri-implant mucositis (PIM), bone loss (BL), and immediate postoperative complications. MATERIAL AND METHODS: Two groups, including 16 pharmacologically immunosuppressed LTP and 16 matched controls, received 52 and 54 implants, respectively, between 1999 and 2008. After evaluating the postoperative healing, a mean follow-up of more than 8 years was carried out, and radiographic, clinical, and periodontal parameters were recorded to evaluate implant survival and implant- and patient-dependent outcomes. RESULTS: The early postsurgical complications were similar in both groups. Implant survival rate was 100% in the LTP group and 98.15% in the CG. PIM was diagnosed in 35.42% of the implants and 64.29% of the patients of LTP group (LTPG) and in 43.40% of the implants and 56.25% of the patients in the CG. PI was detected in 4.17% of the implants and 7.10% of the patients in the LTPG and in 9.43% of the implants and 18.80% of the patients in the CG. CONCLUSION: Pharmacologically immunosuppression in liver transplant patients was not a risk factor for implant failure, nor for the incidence of peri-implant diseases. Liver transplant is not a contraindication for dental implant treatment, although these patients should be carefully monitored during follow-up care.

来源:Clin Oral Implants Res,查看原文。版权归原作者所有。

引用

  1. Paredes V, López-Pintor RM, Torres J, et al. Implant treatment in pharmacologically immunosuppressed liver transplant patients: A prospective-controlled study. Clin Oral Implants Res. 2017. PMID: 28733984. doi:10.1111/clr.13035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。